Efficacy of Adjuvant Nivolumab versus Adjuvant Gemcitabine plus Cisplatin/Carboplatin after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Real-World Analysis Using a Japanese Large-Scale Claims Database
Urologia Internationalis · 2026-10-15 · 1-1
DOI: 10.1159/uin/aewag029 ↗Abstract
Introduction: Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy with a poor prognosis. Although adjuvant platinum-based chemotherapy is a standard treatment after radical nephroureterectomy (RNU), the efficacy of adjuvant nivolumab in UTUC remains unclear, especially in real clinical practice. We examined this using a large Japanese real-world database. Methods: Using the Medical Data Vision database, we identified UTUC patients who underwent RNU and received adjuvant therapy. The adjuvant GC/GCarbo group and the adjuvant nivolumab group were defined by distinct treatment eras to reduce treatment selection bias. Event-free survival (EFS) was compared using Kaplan-Meier curves and the log-rank test, with a sensitivity analysis truncating follow-up at 300 days. Results: A total of 1,058 patients were analyzed (240 nivolumab, 818 GC/GCarbo). In the whole cohort, EFS was significantly longer in the nivolumab group (HR = 0.6365, p = 0.0076). This association was consistent in patients with neoadjuvant chemotherapy (HR = 0.4053, p = 0.001) and in those without it (HR = 0.6765, p = 0.0462). Conclusion: In Japanese UTUC patients, adjuvant nivolumab was associated with a longer EFS than GC/GCarbo. Because this was an unadjusted, observational comparison, the finding should be interpreted with caution and regarded as hypothesis-generating.
EUVIMED